PCSK9 and familial hyperaldosteronism: A recent real-world study demonstrated that in patients with FH treated with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the mean LDL-cholesterol level at 24 months was 79.7 (45.9) mg/dL in those with HeFH and 95.1 (60.2) mg/dL in those with homozygous FH [76].